These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 17143194

  • 1. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J.
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [Abstract] [Full Text] [Related]

  • 2. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL.
    Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):327-33. PubMed ID: 21846154
    [Abstract] [Full Text] [Related]

  • 3. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
    Lacourcière Y, Taddei S, Konis G, Fang H, Severin T, Zhang J.
    J Hypertens; 2012 Oct 01; 30(10):2047-55. PubMed ID: 22828090
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR, Sun NL, Yang K, Hu J, Xu G, Hong H, Wang R, Tu YM, Ritter S, Keefe D, trial investigators.
    Hypertens Res; 2012 Jan 01; 35(1):28-33. PubMed ID: 21900941
    [Abstract] [Full Text] [Related]

  • 5. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial.
    Braun-Dullaeus RC, Shustov SB, Alvarez C, Rogelio GG, Zhang J, Hristoskova S, Häring DA.
    Int J Clin Pract; 2012 Sep 01; 66(9):834-42. PubMed ID: 22897460
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
    Yan JH, Jarugula V, Sabo R, Papst CC, Zhang J, Dole WP.
    J Clin Pharmacol; 2012 May 01; 52(5):645-55. PubMed ID: 21659626
    [Abstract] [Full Text] [Related]

  • 7. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
    Ferdinand KC, Weitzman R, Purkayastha D, Sridharan K, Jaimes EA.
    J Am Soc Hypertens; 2012 May 01; 6(3):219-27. PubMed ID: 22305998
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
    Sica D, Gradman AH, Lederballe O, Kolloch RE, Zhang J, Keefe DL.
    Clin Drug Investig; 2011 Dec 01; 31(12):825-37. PubMed ID: 22035463
    [Abstract] [Full Text] [Related]

  • 9. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
    Liu Y, Yan R, Song A, Niu X, Cao C, Wei J, Dong X, Gao D.
    Am J Hypertens; 2014 Feb 01; 27(2):268-78. PubMed ID: 24304656
    [Abstract] [Full Text] [Related]

  • 10. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
    Townsend RR, Forker AD, Bhosekar V, Yadao A, Keefe DL.
    J Clin Hypertens (Greenwich); 2011 Dec 01; 13(12):889-97. PubMed ID: 22142348
    [Abstract] [Full Text] [Related]

  • 11. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
    Ambrosioni E, Bombelli M, Cerasola G, Cipollone F, Ferri C, Grazioli I, Leprotti C, Mancia G, Melzi G, Mugellini A, Mulè G, Palasciano G, Salvetti A, Trimarco B.
    Adv Ther; 2010 Jun 01; 27(6):365-80. PubMed ID: 20556561
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.
    Sohn IS, Kim CJ, Oh BH, Hong TJ, Park CG, Kim BS, Chung WB, Investigators.
    Am J Cardiovasc Drugs; 2016 Apr 01; 16(2):129-38. PubMed ID: 26691333
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study.
    Villa G, Le Breton S, Ibram G, Keefe DL.
    J Clin Pharmacol; 2012 Dec 01; 52(12):1901-11. PubMed ID: 22174431
    [Abstract] [Full Text] [Related]

  • 14. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
    Volman S, Benitez FN, Cedenio H, Giorgi M, Jaramillo N, Molina N, Zilberman J.
    Ther Adv Cardiovasc Dis; 2013 Aug 01; 7(4):189-96. PubMed ID: 23723254
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
    Littlejohn TW, Jones SW, Zhang J, Hsu H, Keefe DL.
    J Hum Hypertens; 2013 May 01; 27(5):321-7. PubMed ID: 23076450
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.
    Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo JL.
    Cardiovasc Drugs Ther; 2012 Apr 01; 26(2):145-55. PubMed ID: 22311004
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Ritter S, Zhang J.
    Curr Med Res Opin; 2010 Dec 01; 26(12):2841-9. PubMed ID: 21062137
    [Abstract] [Full Text] [Related]

  • 18. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E.
    Hypertens Res; 2011 Mar 01; 34(3):308-13. PubMed ID: 21124333
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of aliskiren 300  mg/hydrochlorothiazide 25  mg (± amlodipine 5  mg) in hypertensive patients not controlled by candesartan 32  mg plus HCT 25  mg.
    Schweizer J, Ulmer HJ, Benduhn H, Klebs S.
    Curr Med Res Opin; 2011 Jan 01; 27(1):131-40. PubMed ID: 21117946
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study.
    Smith TR, Glazer RD, Koren MJ, Wernsing M, Zhang Y.
    Int J Clin Pract; 2010 Sep 01; 64(10):1367-74. PubMed ID: 20716145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.